Get the Stockscreener App
1.17
4.46%
0.05
Hcw Biologics Inc stock is traded at $1.17, with a volume of 80,415.
It is up +4.46% in the last 24 hours and down -29.52% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
See More
Previous Close:
$1.12
Open:
$1.12
24h Volume:
80,415
Relative Volume:
0.29
Market Cap:
$2.62M
Revenue:
$6.59M
Net Income/Loss:
$-18.12M
P/E Ratio:
-0.1237
EPS:
-9.4605
Net Cash Flow:
$-11.45M
1W Performance:
-5.65%
1M Performance:
-29.52%
6M Performance:
-52.36%
1Y Performance:
-95.00%
1-Day Range:
$1.09
$1.1908
1-Week Range:
$1.09
$1.34
52-Week Range:
$1.09
$24.42
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
1.17 | 2.62M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics Announces Special Meeting for Stockholder Vote on Warrant Issuance Linked to July 2026 Private Placement - Kalkine Media
HCW Biologics Announces Strategic $1.5 Million Financing - TipRanks
HCW Biologics Prices $1.5 Million Private Placement With Existing Stockholder - Quiver Quantitative
HCW Biologics Announces Pricing of $1.5 Million Private Placement - GlobeNewswire
Clinical trials and drug studies are among the planned uses for proceeds from HCW Biologics' $1.5 million deal. - Stock Titan
HCW Biologics Board Withdraws Performance Equity Plan Proposal After Stockholder Feedback - minichart.com.sg
HCW Biologics Updates Special Meeting Proxy Materials - TipRanks
HCW Biologics removes equity-plan proposal, reschedules special meeting - TradingView
HCW Biologics (HCWB) asks holders to lift warrant share cap - Stock Titan
HCWB Looks 92.8% Undervalued on GF Value™ Despite Financial Dist - GuruFocus
HCW Biologics signs global HCW11-006 distribution deal - TipRanks
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent - Yahoo Finance
HCW Biologics signs distribution deal with Akron Biotech By Investing.com - Investing.com Canada
HCW Biologics signs distribution deal with Akron Biotech By Investing.com - Investing.com India
HCWB Stock In Focus As Holders File To Sell 1.24M Shares - timothysykes.com
HCWB Stock Faces Pressure As Shareholders Plan Secondary Sale - stockstotrade.com
HCW Biologics signs distribution deal with Akron Biotech - Investing.com
HCW Biologics Enters Exclusive Distribution Agreement with Akron Biotech for HCW11-006 Reagent Commercialization - Quiver Quantitative
A reagent may help make longer-lasting immune cells. HCW Biologics will supply it to Akron. - Stock Titan
Hcw Biologics Stock Price Forecast. Should You Buy HCWB? - StockInvest.us
HCW Biologics (NASDAQ: HCWB) asks investors to vote on more equity than its current share count - Stock Titan
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - Investing News Network
HCWB Looks 90.0% Undervalued on GF Value™ - GuruFocus
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - The Manila Times
HCW Biologics Strengthens U.S. Patent Estate for Its Lead - GlobeNewswire
HCW Biologics Inc. SEC Filing (Sep 1, 2026) - Stock Titan
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceBackspread Trade - siam.in
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceInstitutional Flow Picks - dars.gov.et
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Canada
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Nigeria
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com India
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com UK
Human studies showed HCW Biologics’ fusion expanded progenitor T cells and natural killer cells - Stock Titan
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com
HCW (HCWB) Financial Update: The EPS Result Is Above Expectation in the Latest Reading; Investor Response: The Share Price Adds 2.83% on the DayEarnings Call Transcript - vinanet.vn
HCW (HCWB): Finishes 2.83% Up at $2.18 in the Latest Reading; Range Check: Price Remains Between $2.07 Support and $2.29 ResistanceBPI Bull Confirmed - vinanet.vn
HCW Biologics (NASDAQ: HCWB) registers PIPE, warrant shares - Stock Titan
581,047 Common Stock of HCW Biologics Inc. are subject to a Lock-Up Agreement Ending on 20-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
HCWB Q1 2026 Earnings: EPS of $2.22 Smashes Consensus by 182.44% Despite No RevenueHigh Estimate Range - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusDividend Arbitrage - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusInvestment Factor - dars.gov.et
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results - The Manila Times
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusBollinger Squeeze - dars.gov.et
HCW Biologics regains Nasdaq bid price compliance - scanx.trade
HCW Biologics requests FDA meeting for HCW11-018b solid tumor candidate - scanx.trade
HCW Biologics Q2 net loss widens to $5.2M despite revenue surge - scanx.trade
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Nigeria
HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary - TradingView
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Australia
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hcw Biologics Inc Stock (HCWB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flowers Lee | SVP of Business Development |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
8,691 |
| GARRETT SCOTT T | Director |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
41,644 |
| Wong Hing C | Chief Executive Officer |
May 22 '26 |
Buy |
1.41 |
113,879 |
160,000 |
615,790 |
| GARRETT SCOTT T | Director |
May 22 '26 |
Buy |
1.41 |
177,936 |
250,000 |
203,441 |
| Byam Rebecca | Chief Financial Officer |
May 22 '26 |
Buy |
1.41 |
14,235 |
20,000 |
57,245 |
3.09%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):